Pulmonx (LUNG) Cash & Equivalents (2019 - 2025)

Pulmonx (LUNG) has 7 years of Cash & Equivalents data on file, last reported at $69.8 million in Q4 2025.

• Cash & Equivalents for Q4 2025 came in at $69.8 million, down 1.63% year-over-year; the trailing twelve-month figure through Dec 2025 was $69.8 million (down 1.63% YoY), and the FY2025 annual result was $69.8 million, down 1.63% from the prior year.
• Cash & Equivalents slipped to $69.8 million in Q4 2025 per LUNG's latest filing, from $76.5 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $209.3 million in Q1 2021 and troughed at $63.3 million in Q3 2024.
• A 5-year average of $108.2 million and a median of $98.3 million in 2023 frame the typical range for Cash & Equivalents.
• The sharpest annual moves came in 2021 and 2022: Cash & Equivalents jumped 1188.61% in 2021, then plunged 40.24% in 2022.
• A 5-year view of Cash & Equivalents shows it stood at $148.5 million in 2021, then sank by 31.48% to $101.7 million in 2022, then slipped by 17.88% to $83.5 million in 2023, then declined by 15.13% to $70.9 million in 2024, then fell by 1.63% to $69.8 million in 2025.
• Business Quant data shows LUNG's Cash & Equivalents at $69.8 million in Q4 2025, $76.5 million in Q3 2025, and $75.5 million in Q2 2025.